Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study)

ET remains the most used first-line treatment in Brazil. However, access to therapies varies significantly between public and private healthcare sectors. This disparity highlights inequality in access to treatment.

Authors

Institutions

Publication Details

Journal
Clinical Breast Cancer
Published
2025-05-27
DOI
https://doi.org/10.1016/j.clbc.2025.05.020
Citations
2
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
3.04
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study)

Maiane Maria Pauletto, Poliana Signorini, Tomás Reinert, Fernando Castilho Venero et al.
2 citations
Clinical Breast Cancer
Advanced Breast Cancer Therapies
3.04
article

Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study)

Maiane Maria Pauletto, Poliana Signorini, Tomás Reinert, Fernando Castilho Venero, José Bines, Rafaela Gomes de Jesus, Luiza Nardin Weis, Jorge Henrique Santos Leal, Eduardo Cronemberger, Daniela Dornelles Rosa, Aline Bomfim Vieira, Miguel Guimarães, Heloísa Resende, Tatiana Correa, Juliana Góes Martins Fagundes, Gustavo Gössling, Romualdo Barroso‐Sousa, Ana Oliveira, Luísa Mostardeiro Tabajara Franche, Gustavo Werutsky, José Márcio Barros de Figueiredo, Marina Musse Bernardes
article en
2 citations

Abstract

ET remains the most used first-line treatment in Brazil. However, access to therapies varies significantly between public and private healthcare sectors. This disparity highlights inequality in access to treatment.

Clinical Breast CancerVol. 25(8)
Instituto Nacional de Pesquisas da Amazônia (BR), MedSIR (Spain) (ES), Instituto do Cérebro de Brasília (BR), Instituto de Oncologia do Paraná (BR), Instituto de Neurologia de Curitiba (BR), Centro de Pesquisas Oncológicas (BR), Pontifícia Universidade Católica do Rio Grande do Sul (BR)
Good health and well-being
Openalex Percentile: Top 9%
Advanced Breast Cancer Therapies
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.